Skystar Bio-Pharmaceutical to File Financial Results for Second Quarter of Fiscal 2014 on Thursday, August 14

Skystar Bio-Pharmaceutical to File Financial Results for Second Quarter of 
Fiscal 2014 on Thursday, August 14 
Conference Call to Follow Friday, August 15, 2014 at 7:45 AM (ET) 
XI'AN, CHINA -- (Marketwired) -- 08/14/14 --   Skystar
Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the
"Company"), a China-based manufacturer and distributor of veterinary
medicines, vaccines, micro-organisms and feed additives, will file
its financial results for the second quarter of fiscal 2014 on
Thursday, August 14, 2014 by close of the business day. 
Conference Call Information
 The Company will host a conference call
on Friday, August 15, 2014 to discuss its financial results for the
quarter ended June 30, 2014. Skystar's conference call will begin
promptly at 7:45 a.m. EDT to review second quarter fiscal 2014
financial and operational performance. Mr. Weibing Lu, Skystar's
Chairman and Chief Executive Officer, will host the call, which will
be webcast live.  
Webcast will be made available on the investor relations section of
the Skystar corporate website at
http://www.investorcalendar.com/IC/CEPage.asp?ID=173097. 
Phone dial-in to the conference call will be available in North
America by dialing +1 (877) 407-8031 or internationally by dialing +1
(201) 689-8031.  
An audio replay of the conference call will be available
approximately two hours following the conclusion of the call and for
the following 30 day period. To access the replay in North America,
dial +1 (877) 660-6853 or, when calling internationally, dial +1
(201) 612-7415, referencing conference ID # 13589170.  
To be added to the Company's email distribution for future news
releases, please send your request to skystar@taylor-rafferty.com. 
About Skystar Bio-Pharmaceutical Company
 Skystar is a China-based
developer, manufacturer and distributor of veterinary healthcare and
medical care products. Skystar has four product lines: veterinary
medicines, probiotics, vaccines and feed additives formulated and
packaged in house across several modern manufacturing and
distributions facilities. Skystar's distribution network includes
almost 3,000 distribution agents of which 360 are franchised stores
with exclusivity agreements covering 29 provinces throughout China.
For additional inf
ormation, please visit
http://www.skystarbio-pharmaceutical.com.  
Safe Harbor Statement under the Private Securities Litigation Reform
Act of 1995 
 Safe Harbor Statement under the Private Securities
Litigation Reform Act of 1995: Certain of the statements made in the
press release constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
These statements can be identified by the use of forward-looking
terminology such as "believe," "expect," "may," "will," "should,"
"project," "plan," "seek," "intend," or "anticipate" or the negative
thereof or comparable terminology. Such statements typically involve
risks and uncertainties and may include financial projections or
information regarding the progress of new product development. Actual
results could differ materially from the expectations reflected in
such forward-looking statements as a result of a variety of factors,
including the risks associated with the effect of changing economic
conditions in The People's Republic of China, variations in cash
flow, reliance on collaborative retail partners and on new product
development, variations in new product development, risks associated
with rapid technological change, and the potential of introduced or
undetected flaws and defects in products, and other risk factors
detailed in reports filed with the Securities and Exchange Commission
from time to time. 
Contacts: 
Skystar Bio-Pharmaceutical Company
Scott Cramer
Director - Corporate Development & U.S. Representative
(407) 645-4433 
Grayling 
Investor Relations
Christopher Chu 
(908) 251-9869
skystar@taylor-rafferty.com 
 
 
Press spacebar to pause and continue. Press esc to stop.